Drug Type Oncolytic bacteria |
Synonyms genetically modified Salmonella comprising of methioninase, SalMet-Vec, SGN 1 + [1] |
Target- |
Mechanism Bacteria replacements |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
RegulationOrphan Drug (US) |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Squamous Cell Carcinoma of Head and Neck | Phase 2 | CN | 17 Apr 2024 | |
Advanced Malignant Solid Neoplasm | Phase 2 | US | 23 Dec 2022 | |
Melanoma | Phase 1 | - | 10 Nov 2022 | |
Hepatocellular Carcinoma | Preclinical | US | 10 Nov 2022 | |
Hepatocellular Carcinoma | Preclinical | CN | 10 Nov 2022 | |
Non-Small Cell Lung Cancer | Preclinical | CN | 10 Nov 2022 | |
Osteosarcoma | Preclinical | US | 10 Nov 2022 | |
Osteosarcoma | Preclinical | CN | 10 Nov 2022 | |
Small Cell Lung Cancer | Preclinical | US | 10 Nov 2022 | |
Small Cell Lung Cancer | Preclinical | CN | 10 Nov 2022 |